650
Participants
Start Date
April 30, 2021
Primary Completion Date
February 9, 2023
Study Completion Date
February 9, 2023
Oral semaglutide
Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
Master Centre for Japan, Tokyo
Lead Sponsor
Novo Nordisk A/S
INDUSTRY